Genmab — Marts 2021

[E_L]

so I guess we learned there is a maximum to the time JNJ can think about HexaBody-CD38 , which is they 'can in theory wait for the clinical data from two clinical studies'

[E_L]

I don't understand why he didn't give us the Dara price hike; he did so the last 2 times? Maybe there was no hike... Has anyone seen it anywhere else?

[Helge_LarsenPI-redaktør]

Tak GB og tusinde tak til alle for de skarpe spørgsmål. Desværre var der ikke plads til dem alle indenfor tidsrammen.

[Solsen]

CD37 glæder jeg mig også til...

[Bulder]

I morgen kommer der SH-tal. Holder du udkig Helge? Gerne for januar også.

[Solsen]

Masser af potentiale i de stoffer vi kender.

[E_L]

Dara up to 14% of the frontline patients, last time we heard i think
was 12%?

[Helge_LarsenPI-redaktør]

Jeps Bulder.

[Plimsoller]

Glofitamab.

[Plimsoller]

Gennembrud i kræftbehandling: »På mindre end et døgn svandt tumorerne ind og blev bløde«

B.T. (www.bt.dk)

[Solsen]

Mærkeligt at jeg ikke kan finde hexa-cd38 på CT. Men på EUs liste https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003781-40/SE

[E_L]

the question on Tisotumab Vedotin was not very precise, but i think Jan is referring to peak sales for cervical cancer there; that amount could get much higher if it works in other indications

[Solsen]

I linket som plimsoller lagde op er endnu et link, hvor bispecifikke i solide omtales positivt. Kunne være Gen1046 https://sundhedspolitisktidsskrift.dk/nyheder/4467-behandlingsrevolution-indenfor-lymfekraeft-vi-har-set-hvordan-tumorerne-pa-mindre-end-et-dogn-svandt-ind-og-blev-helt-blode-det-er-naermest-uvirkeligt.html og bemærk at epco er med i omtalen.

[E_L]

@Solsen ; it isn't on CT yet, i also searched for it a while ago; I actually wondered if Genmab was hoping they will not have to go through the trouble and JNJ will choose to opt in soon and do it for them...

[E_L]

and on 16:41 ; it is; Hutchings is working on both Glofi and Epco

[E_L]

it is taken from the article in the 13:43 link i believe

[GeorgeBest]

Epco has the lead over glofi on safety and subcu, it might of course change if Roche a subcu version for glofi, but so far there is not clear proof of that.

[GeorgeBest]

develope a subcu version

[Solsen]

Det er nok snarere Gen1042 https://clinicaltrials.gov/ct2/show/NCT04083599?term=Gen1042&draw=2&rank=1 i tarmkræft

[Solsen]

Der bliver nok plads til både epco og glofi. Men effektivitet og sc kan godt betyde en skævdeling af markedet. Men ganske imponerende må man være. Bl.a. dlbcl har været en meget vanskelig sygdom at få effekt i. Men epco har fremragende data her.